Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 25Gemcitabine 21Nivolumab 17Cisplatin 17atezolizumab 14Carboplatin 11avelumab 9vinflunine 7Ipilimumab 7Paclitaxel 6Docetaxel 5enfortumab vedotin 4cabazitaxel 4Pemetrexed 4Mitomycin 4cabozantinib 3Taxes 3Rogaratinib 3Magnetic Resonance Spectroscopy 3Injections 3Albumin-Bound Paclitaxel 3tremelimumab 2sacituzumab govitecan 2pemigatinib 2niraparib 2lenvatinib 2bempegaldesleukin 2apatorsen 2XRP6258 2Vitamin D 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Transitional Cell × Panvac-VF × Clear all
NCT02015104 2025-07-01

Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
32 enrolled 16 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡